Welcome to our dedicated page for STEPAN CO SEC filings (Ticker: SCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Stepan Company filings document the regulatory record for a specialty and intermediate chemicals manufacturer whose common stock trades on the New York Stock Exchange under symbol SCL. Its 8-K filings report operating results, dividend declarations, material-event disclosures, capital-structure information and exit or disposal activities tied to manufacturing and efficiency initiatives.
Stepan proxy and annual-meeting filings cover director elections, advisory compensation votes, auditor ratification, executive compensation governance and benefit-plan matters. The filing record also includes disclosure on restructuring charges, asset write-downs, decommissioning costs and other governance or financial matters reported through current reports and proxy materials.
STEPAN CO Vice President and Chief Financial Officer Ruben Dario Velasquez reported multiple equity-based awards and an administrative correction. On March 2, 2026, he received 8,586 Stock Appreciation Rights tied to common stock with a conversion/exercise price of $50.06 and expiration on March 3, 2036. He was also granted 2,996 performance shares, which vest upon certification that performance goals for the period ending December 31, 2028 are achieved, and 5,993 restricted stock units that vest ratably over three years beginning on the grant date. In a separate award dated February 27, 2026, he acquired 35.601 shares of common stock at $52.51 per share. This Form 4/A amends a prior filing solely to correct the Stock Appreciation Right conversion/exercise price to $50.06 from $17.47; no other terms of the reported transactions are changed.
STEPAN CO executive Robert Joseph Haire reported multiple equity awards and corrected prior pricing details. The filing shows grants on March 2, 2026 of 8,586 Stock Appreciation Rights tied to common stock at a conversion/exercise price of $50.06, 2,996 performance shares, and 5,993 restricted stock units.
He also acquired 56.765 shares of common stock at $52.51 per share, bringing direct common stock holdings to 2,538.765 shares, plus 90.269 shares held indirectly through an ESOP II Trust. This Form 4/A amends a prior report only to correct the Stock Appreciation Right exercise price from $17.47 to $50.06; all other aspects of the reported transaction remain unchanged.
STEPAN CO President & CEO Luis Rojo reported several equity compensation awards. On March 2, 2026, he received 57,241 stock appreciation rights with a conversion price of $50.06, 39,952 performance shares, and 19,976 restricted stock units, each tied to one share of common stock. On February 27, 2026, he was granted 56.765 shares of common stock at $52.51. The filing also corrects an earlier Form 4 by revising the SAR conversion price to $50.06 from $17.47 due to an administrative error.
STEPAN CO director F. Painter Corning received a stock award of 2,566 shares of Common Stock on May 8, 2026. The grant is recorded at a price of $52.61 per share and is classified as a grant, award, or other acquisition rather than an open-market purchase. Following this non-derivative equity award, Corning directly holds 4,999 shares of Stepan common stock. This reflects routine director compensation in equity form, not a discretionary market trade.
STEPAN F QUINN JR reported acquisition or exercise transactions in this Form 4 filing.
STEPAN CO director Quinn Stepan Jr. reported a stock award of 2,566 shares of common stock on May 8, 2026, received as a grant rather than an open-market purchase, at a reported price of $52.61 per share. After this award, his directly held common stock position stands at 143,007.262 shares.
The filing also updates a series of indirect holdings in various related entities and family accounts, showing post-transaction balances such as 160,000 shares held by a Family LLC and 87,500 shares held by Family Trust IV, among others. Several other indirect entries, including certain family trusts and plan-related positions, are shown with zero balances, reflecting current reported holdings rather than clear buy or sell activity.
STEPAN CO director Jan Stern Reed received a grant of 2,566 shares of Common Stock on May 8, 2026. The award is recorded at $52.61 per share and is classified as a grant, award, or other acquisition rather than an open-market purchase. Following this equity award, Reed directly holds 16,477 shares of STEPAN CO Common Stock.
Lewis Susan reported acquisition or exercise transactions in this Form 4 filing.
Stepan Co director Susan Lewis received a compensation-related grant of 2,566 shares of Common Stock on May 8, 2026, at a price of $52.61 per share. Following this award, her directly held stake increased to 6,962 shares of Stepan Co common stock.
STEPAN CO director Joaquin Delgado received a grant of 2,566 shares of Common Stock on May 8, 2026. The award is recorded at $52.61 per share, reflecting a compensation-related acquisition rather than an open-market purchase. Following this grant, Delgado directly holds 18,637 shares of Stepan common stock.
Burgess Lorinda reported acquisition or exercise transactions in this Form 4 filing.
STEPAN CO director Lorinda Burgess received a grant of 2,566 shares of Common Stock on May 8, 2026. The award was recorded at a price of $52.61 per share, reflecting compensation rather than an open-market purchase. Following this grant, she directly holds 5,900 Common Stock shares in total.
STEPAN CO director Randall S. Dearth received a grant of 2,566 shares of Common Stock on May 8. The shares were awarded at a reference price of $52.61 per share and are characterized as a grant, award, or other acquisition rather than an open-market purchase. Following this compensation-related award, his direct holdings increased to 16,672 shares of STEPAN CO Common Stock, indicating a routine adjustment to his equity position as a board member.